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6Abstract
Tinidazole, chemically 1-[2-(ethylsulfonyl)ethyl]−2-methyl−5-nitroimidazole, as well as
metronidazole and ornidazole, are 5-nitroimidazole drugs which are commonly used against
amoebiasis, giardiasis, trichomoniasis, and anaerobic bacterial infections in humans. All
5-nitroimidazoles are synthetic drugs.
Stability studies on drugs are important not only for the correct preparation and storage of
drug compounds and preparations, but they also provide useful information on degradation
products and pathways, as well as valuable material for the development and validation of
analytical methods. Spectrophotometric, chromatographic, voltammetric, and titrimetric
methods of analysis have been widely applied to the quantitative determination of
5-nitroimidazoles.
A high−performance liquid chromatographic (HPLC), a high−performance thin layer
chromatographic (HPTLC), and two ultraviolet (UV) spectrophotometric methods were
developed and used for the quantitation of tinidazole in hydrolyzed aqueous solutions. The
HPTLC and UV spectrophotometric methods were validated and shown to be stability−
indicating. The UV methods were sensitive to the reaction pH, whereas the chromatographic
methods could be used for analyzing tinidazole solutions hydrolyzed at pH 1−12. The
feasibility of systematic wavelength searching in developing multi−wavelength
spectrophotometric methods was demonstrated using the precision and accuracy of validation
samples as selection criteria.
The hydrolysis of tinidazole followed apparent first−order kinetics in most of the conditions
studied. It was hydrolytically most stable at pH 4.0−5.0. It was demonstrated that at least one
of the reacting partners contributing to the transition state had a charge of 0 in the major
degradation pathway at various pH values. The dominant reactions were tinidazole + OH− at
pH ≥ 7 and tinidazole + H2O at a pH of around 4.5. In more acidic conditions, the reactions
tinidazole + H+ and/or [tinidazole+H]+ + H2O took place, but the existence of
[tinidazole+H]+ + H+ could not be excluded nor corroborated. A mechanism for the alkaline
hydrolysis was suggested, and it involved a proton transfer from tinidazole to the hydroxide
ion and the formation of ethyl vinyl sulfone. The reaction may occur in either a step−wise or a
7concerted manner. The reaction was qualitatively verified by computational methods, but the
activation energy of the hydrolysis reaction, which was determined to be ca. 120−130 kJ/mol,
could not be reproduced. The two known hydrolysis products were detected at pH 6−12, but
they were absent at pH ≤ 5. No other 5−nitroimidazole products were detected in hydrolyzed
tinidazole solutions at pH 1−12.
81. Introduction
Three 5−nitroimidazole drugs, namely metronidazole, ornidazole, and tinidzole, have been
available in Finland on prescription (Figure 1.1). At present, only metronidazole preparations
are on the market [1]; ornidazole and tinidazole were withdrawn in 1993 [2] and 1995 [3],
respectively. However, all three drugs, as well as other 5−nitroimidazoles, are currently used
as human drugs in several European and non−European countries; some 5−nitroimidazoles
have also found potential use in veterinary practice [4]. However, these 5−nitroimidazoles
belong to a list [5] of compounds for which no maximum levels in foodstuffs of animal origin
can be fixed.
Figure 1.1: The structures of metronidazole, ornidazole, and tinidazole.
Medicinal interest in nitroimidazoles arose from the observation that azomycin, later [6]
identified as 2−nitroimidazole, possessed antimicrobial activity [7]. Azomycin originates from
a soil sample [7], while the 5−nitroimidazoles are synthetic drugs. The first 5−nitroimidazole
drug to come on the market was metronidazole [8]; since then, several others have been
synthesized and used as drugs, including ornidazole [9] and tinidazole [10]. The tautomeric
2-methyl−4(5)-nitroimidazole is the common starting material for their synthesis [9−11].
5-nitroimidazoles are mainly used against amoebiasis, giardiasis, trichomoniasis, and
anaerobic bacterial infections [4,12]. 4−nitroimidazoles are much less active than the
corresponding 5-nitro isomers [11]. Also, metronidazole and tinidazole have been used in the
eradication of Helicobacter pylori [4]. Very recently, several diarylmethyl ethers of
metronidazole were shown to possess submicromolar activity against HIV-1 [13]. The
structure−activity relationships of hundreds of 5-nitroimidazoles have been studied [14−19],
and comprehensive reviews [12,20] on their chemistry and pharmacology exist.
N
N CH3O2N
CH2CH2SO2CH2CH3
N
N CH3O2N
CH2CH2OH
N
N CH3O2N
CH2CHCH2Cl
OH
metronidazole ornidazole tinidazole
9Ebel et al. [21] published a review article on the stability−indicating assays for metronidazole.
Their list included ultraviolet/visible (UV/Vis) spectrometry, high−performance thin layer
chromatography (HPTLC), high−performance liquid chromatography (HPLC), and
voltammetry; titrimetry, the pharmacopoeial [22] method of choice, is not suited for the
purpose since interference by the degradation products is to be expected [21]. All techniques
are applicable for most, if not all, 5-nitroimidazoles. However, the list is not exhaustive, and
e.g. gas chromatography, which has been used for the quantitative analysis of
5-nitroimidazoles [23], provides comparable capabilities. It is the nitro group that is
responsible for electron capture in the electrochemical methods of analysis [24] and, in
conjugation with the imidazole moiety, it lies in the heart of the UV spectrophotometric
methods. The latter property especially constitutes a convenient method of detection in
HPTLC and HPLC.
The validation of an analytical method is an integral part of method development since its
purpose is to demonstrate that the method is appropriate for the intended application. Since
1996, an ICH guideline final draft [25] has existed for the methodology with an associated text
[26]; all ICH guidelines concerning analytical methods, and quality in general, are accessible
on the ICH Quality Topics homepage (http://www.ich.org/ich5q.html). Being guidelines, the
ICH documents cannot go into details, and the analyst may still need to resort to the scientific
literature in order to find the proper procedures for individual validation tests. (HP)TLC is an
off−line technique that serves as an excellent example of an analytical method that imposes
additional requirements on the validation scheme: the analytes on the plate are vulnerable to
oxidative degradation catalyzed by the free silanol groups and light [27] both before, during,
and after the chromatographic separation. A less than exhaustive list of publications on the
validation of HPTLC methods is shortly reviewed in paper II.
The objective of this study was to develop HPLC, HPTLC, and UV spectrophotometric
methods for investigating the hydrolytic stability of tinidazole over a wide pH range. The
alkaline hydrolysis mechanism of tinidazole was also studied.
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2. Review of the literature
2.1. Stability of 5−nitroimidazoles
"Examining degradation products under stress conditions is useful in establishing degradation
pathways and developing and validating suitable analytical procedures" [28]. Being sufficient
for a registration application in the European Union, Japan, and the United States, the stability
testing of new drug substances and products is covered in two ICH guidelines [28,29]. Stress
testing should establish the effect on stability of temperature, humidity, oxidation, and
photolysis; hydrolytic stability over a wide range of pH values should also be studied for
substances in solution or suspension [28]. The general testing conditions are listed in Table
2.1. Photostability testing is described in another guideline [29].
Table 2.1: General conditions for stability testing of new drug substances [28].
Study Storage condition Minimum time period covered by data at submission of registration
application
Long term 25±2 °C and 60±5 % relative humidity 12 months
Intermediate 30±2 °C and 60±5 % relative humidity 6 months
Accelerated 40±2 °C and 75±5 % relative humidity 6 months
2.1.1. Photolysis
The photolytic disintegration of 5−nitroimidazoles is a versatile reaction. The initial formation
of a nitro radical anion has been proposed [30] as one reaction pathway; this has later [31]
been shown to be incorrect for metronidazole. The radical anion would then decompose to
yield nitrite or the corresponding amine by multistep reduction [32]; other reports [33,34]
proposing different mechanisms also exist. By far the most complete reaction sequence
described involves several rearrangements of the 5−nitroimidazole structure. This sequence
(Scheme 2.1) has been verified [33,35,36] for the compounds in Table 2.2; the side chain on
the imidazole N1 has to be a group other than hydrogen for the reaction to take place [35]. The
reaction proceeds via the very labile tautomeric 2−imidazoline−4,5−dione−4−oxime (2) to the
corresponding 1,2,4−oxadiazole−3−carboxamide (3) [33,35,36]. A more detailed reaction
mechanism has been presented as well [33,35]. The oxadiazole is the main photolysis product
for the compounds in Table 2.2 [33,35]. It has also been reported [33] to be the end product of
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the reaction, but other workers [35,36] have shown that the compounds decompose further,
yielding an oxamide (4). The degradation kinetics of several 4− and 5−nitroimidazoles,
including metronidazole, ornidazole, and tinidazole, has been found to be of the first order
both in solution [37] and in the solid state [38]; in solution, metronidazole was by far the most
photolabile 5−nitroimidazole [37].
Table 2.2: 5−Nitroimidazole drugs (1 in Scheme 2.1) known to decompose photolytically
according to Scheme 2.1.
R Generic name Reference
CH3 Dimetridazole [35]
CH2CH2OH Metronidazole [33,35]
CH2CH(OH)CH2Cl Ornidazole [35]
CH2CH(OH)CH3 Secnidazole [35]
CH2CH2SO2CH2CH3 Tinidazole [36]
CH2CH(O−COCH3)CH3 (Secnidazole, acetate ester) [35]
Scheme 2.1
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N
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N
N
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HON
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N
R
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Table 2.3: Liberation of nitrite ions used for the quantitative analysis of 5−nitroimidazole drugs.
Compound R1 R2 Hydrolytic conditions Reference
Dimetridazole CH3 CH3 e.g. 2 h in 0.2 M NaOH under copper catalysis at 100 °C [40]
Ipronidazole CH3 CH(CH3)2
2 h in 0.1 N NaOH at 100 °C [39]
e.g. 2 h in 0.2 M NaOH under copper catalysis at 100 °C [40]
Metronidazole CH2CH2OH CH3 15 min in 1 N NaOH at 100 °C [42]
Nimorazole CH2CH2 N O H 15 min in 2.5 N NaOH at 100 °C [43]
Ornidazole CH2CH(OH)CH2Cl CH3
1 h UV irradiation in 0.1 N NaOH [44]
3 min in 1 N NaOH at 100 °C [43]
Ronidazole CH3 CH2O−CONH2
1 h in 1.67 % NaOH under copper catalysis at 80 °C [45]
e.g. 2 h in 0.2 M NaOH under copper catalysis at 100 °C [40]
Secnidazole CH2CH(OH)CH3 CH3 10 min in 0.5 M NaOH at 100 °C [46]
N
N
R1
R2O2N
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2.1.2. Chemical hydrolysis
According to the approach used, the literature on the hydrolysis reactions can be divided into
two groups: the formation of nitrite ions, and the degradation of the parent compound (with
possible analysis of the emerging products).
Lau et al. [39] reported in 1969 that N1−substituted 5−nitroimidazoles yield quantitative
amounts of nitrite ions when reacted in 0.1 N NaOH at 100 °C for 2 hours; however, the
reaction seemed to be complete in 1 hour (Figure 2 in Ref. [39]). They also demonstrated the
applicability of the reaction for the quantitative analysis of ipronidazole: the nitrite ion so
formed reacts with sulfanilamide and an aromatic amine to produce a colored diazo compound
which can then be quantitated spectrophotometrically. It has since been shown [40] that even
N1−unsubstituted 5−nitroimidazoles can be similarly decomposed in 1.5 M NaOH under
prolonged (up to 5 h) heating at 100 °C and copper catalysis; the alkali concentration can be
used to distinguish the unsubstituted compounds from the substituted ones. This reaction has
been used for the quantitative analysis of several 5−nitroimidazole drugs (Table 2.3); the
diazotization reagents and conditions, as well as the analytical wavelengths (typically
535-550 nm), usually vary. A possible reaction mechanism for the nitrite formation, at least
for 5-nitro−2-styrylimidazoles at pH ≥ 13, has been presented [41]. Theuer [34] demonstrated
the formation of ppm−level nitrite during the autoclavation of metronidazole.
The hydrolysis of metronidazole was a first−order reaction in both acidic and alkaline
conditions [47,48], and it exhibited maximum stability at pH 4−6 [34,47,48]. The alkaline
hydrolysis of metronidazole yielded almost quantitative amounts of ammonia and acetic acid
[49], as well as an amine with at least one attached hydrogen [47,49]; an amine has also been
shown [47] in acid hydrolyzed solutions. A kinetic salt effect was detected at pH 3.1, while it
was less pronounced at pH 7.4 [48]. The defects in the mathematical treatment of the kinetic
data [48] have been pointed out and corrected [50]. The activation energy of hydrolysis was
26.6 kcal/mol at pH 8.0 [47] and 15.35 kcal/mol at pH 3.1 [48]. No general acid/base catalysis
could be detected [48].
As both reactions involve well−known organic chemistry, the pseudo first−order alkaline
hydrolysis (pH 6−10) of ornidazole has been shown to produce an epoxide from the side−
chain chlorohydrin, and subsequently the corresponding diol [51,52] (Fig. 1 in paper V), the
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latter reaction being of pseudo first−order, as well [51]. On the other hand, ornidazole has also
been reported [52] to lose the nitroimidazole structure in strongly acidic conditions (≥ 0.1 M
HCl). 2−methyl−4(5)−nitroimidazole and the 4−nitro isomer of ornidazole, as well as the
previously mentioned epoxide and diol, were already known to the scientific community as
possible impurities of ornidazole [53]. The most recent study [52] is based on the ICH
guideline [28] for stability testing.
Tinidazole is known to decompose hydrolytically in alkaline conditions to its 4−nitro isomer
and 2−methyl−4(5)−nitroimidazole, the latter being the almost exclusive product in 0.1 M
NaOH [36]. These decomposition products are also the only specifically named structurally
related impurities (B and A, respectively) limited by the monograph of tinidazole in the
European Pharmacopoeia [54]. In the presence of a catalytic amount of base, however,
tinidazole has been reported [55] to isomerize almost quantitatively to the 4−nitro isomer; the
corresponding sulfoxides and sulfides do not react. It was suggested [55] that the process takes
place via N−dealkylation followed by N−realkylation on the other nitrogen, involving the
formation of ethyl vinyl sulfone. Indeed, treating 2−methyl−4(5)−nitroimidazole with the
sulfone gave the 4−nitro isomer exclusively [55] and in a high yield [56]. Even before an
insight into the reaction was gained, hydrolysis to 2−methyl−4(5)−nitroimidazole of tinidazole
in strongly alkaline conditions was used for quantifying the drug. A pale yellow color is
produced, thereby facilitating spectrophotometric determinations at 360−370 nm [57−59];
since then, this reaction has been erroneously claimed to be previously unknown [60]. In a
recent study [61], tinidazole was reported to exhibit constant hydrolytic stability over the pH
range 3.00−6.50; the activation energy at pH 5.25 can be calculated to be 133 kJ/mol.
Dimetridazole was not stable when boiled in a mildly alkaline solution, and no decomposition
was observed in a slightly acidic solution. No attempt was made to identify the decomposition
product(s) [62].
2.2. Quantitative analysis of tinidazole
The analytical literature on tinidazole comprises several hundred scientific papers. Therefore,
the following review does not aim to be comprehensive; instead, it is a representative
selection covering three analytical techniques, namely HPLC, (HP)TLC, and
15
UV spectrometry. However, it should be borne in mind that other analytical techniques, like
gas chromatography [23], polarography [63], and titrimetry [22], are also applicable to the
quantitative analysis of tinidazole although they have not been used as frequently in the
literature.
2.2.1. High−performance liquid chromatography
HPLC, which is probably the most frequently used analytical method for the analysis of
tinidazole, has been used to analyze the drug substance in simple formulations [64,65], as well
as in biological samples [64,66−74]. Several methods for stability studies have been
published, too [61,75−79] (Table 2.4). Tinidazole and metronidazole have been frequently
used as internal standard for each other [64,68,71,72,74−78].
2.2.2. High−performance thin layer chromatography
Only a few densitometric thin layer chromatographic (TLC) methods for tinidazole using
silica sorbent have been reported [65,73,81−84] (Table 2.5). The earlier methods [81−83]
apparently made use of conventional TLC plates, while the most recent reports [65,73,84]
with metronidazole as the internal standard are true HPTLC methods. Methods exist for the
analysis of tinidazole in both dosage forms [65,84] and biological samples [73,81−83]. The
earlier method [84] designed for analyzing tinidazole in dosage forms was found to be
comparable with polarography. A study [65] of tinidazole in a combined dosage form (with
furazolidone in suspension) contained no comparison of the HPTLC and HPLC methods
developed. For serum samples, HPTLC was found to produce comparable results with those
given by HPLC [73]. An outdated, laborious, and error−prone method involving scraping and
extraction of the "spots" after chromatography is given for reference [85] only.
Table 2.4: Determination of tinidazole by HPLC.
Mobile phase Column Detection Sample matrix Reference
Acetate buffer (0.05 M, pH 4.7) containing 22 % acetonitrile C18 (30 × 0.4 cm) UV (313 nm) PlasmaTablet [64]
Wateracetonitriletriethylamine 80:20:0.1 (V/V) (pH 3.0 with phosphoric acid) C18 UV (335 nm) Suspension [65]
Phosphate buffer (0.01 M, pH 5.5) with 15 % acetonitrile ODS (5 µm; 0.15 m × 4.6 mm i.d.) UV (320 nm) FecesPlasma [66]
MethanolKH2PO4 (0.005 M, pH 4) 20:80 (V/V) C18 (30 cm × 4 mm i.d.) UV (320 nm) SerumUrine [67]
35 % Acetonitrile in acetate buffer (0.02 M, pH 4.0) C18 (10 µm; 30 × 3.9 mm) UV (313 nm) SerumVarious tissues [68,80]
(No data available.) ODS UV Breast milkSerum [69]
Various compositions (methanol/acetonitrilephosphate buffer) C18 (10 µm) UV (280 nm)
Gingival crevicular fluid
Gingival tissue
Serum
[70]
Methanolwater 23:77 (V/V) C18 (5 µm; 4.6 mm i.d. × 250 mm) UV (310 nm) Saliva [71]
SDS (0.05 M)propan−1−ol 94:6 (V/V) CN (3.9 × 300 mm)
Acetate buffer (0.05 M, pH 4.7) containing 22 % (V/V) acetonitrile C18
UV (320 nm) Serum [72]
Acetate buffer (0.05 M, pH 4.7) containing 22 % acetonitrile C18 (0.39 × 30 cm) UV (313 nm) Serum [73]
KH2PO4 (0.002 M, pH 4.8)methanolacetonitrile 85:7.5:7.5 (V/V) C18 (5 µm; 25 cm × 4.6 mm i.d.) UV (320 nm) Serum [74]
Methanolwateracetic acid 20:80:0.1 ODS (4.6 mm × 20 cm) UV (317 nm) Injection [75]a
Methanolwateracetic acid 20:80:0.5 ODS UV (316 nm) Solution [61]a
Methanolwater 25:75 ODS (5 mm × 150 mm) UV (318 nm) Injection [76]a
Methanolwater 20:80 CLC−ODS (150 × 6.0 mm) UV (310 nm) Injection [77]a
Methanolwateracetic acid 20:80:0.1 ODS (4.6 × 250 mm) UV (310 nm) Collutorium [78]a
AcetonitrileKH2PO4 (0.05 M) 25:75 (4.6 mm × 150 mm) UV (317 nm) Injection [79]a
a
 stability study
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Table 2.5: Determination of tinidazole by thin layer chromatography with densitometric quantitation.
Mobile phase Sorbent Detection Sample matrix Reference
Chloroformacetic acid 9:1 Silica gel F254 Quenching of plate fluorescence Serum [81−83]
Dichloromethaneacetonediethyl ether 2+2+1 (V/V) HPTLC silica gel GF254 Densitometry (311 nm)
Infusion solution
Pure substance
Tablet
[84]
Chloroformacetonitrileacetic acid 60+40+2 HPTLC silica gel 60 Densitometry (320 nm) Serum [73]
Chloroformmethanolammonia 9:1:0.1 (V/V) HPTLC silica gel 60F254 Densitometry (335 nm) Suspension [65]
Table 2.6: Determination of tinidazole by UV spectrophotometry.
Analytical wavelength (solvent) Sample matrix Reference
315 nm (chloroform)
310 nm (alcohol, methanol)
322 nm (benzene)
277 nm (0.1 N HCl)
Bulk drug
Tablet [86]
316 nm (ethanol) Bulk drugTablet [87]
310 nm (ethanol) TLC scrape−off [85]
317±2 nm (water) Medicinal films [88]
317 nm Buccal tabletSaliva [89]
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2.2.3. UV spectrophotometry
Tinidazole has been determined spectrophotometrically as such [86,87], in drug preparations
[86−89], and in biological samples [89] (Table 2.6). An error−prone method using
measurements on n wavelengths for the analysis of n components has been used for tinidazole
in a combined dosage form [90]; the interactions between L−amino acids and tinidazole (and
metronidazole) have been studied as well [91]. Sometimes the other components do not absorb
at the absorption maximum of the component of interest, which can then be determined by a
direct single−wavelength measurement, as was described for tinidazole (311 nm in methanol)
in another combined dosage form [92]. It has been shown [93] that tinidazole (and
metronidazole) sometimes interferes with clinical measurements involving NADH at 340 nm.
However, few methods based on a true multi−wavelength analysis have been published for
tinidazole [94].
2.3. Multi−wavelength methods in spectrophotometry
(True) multi−wavelength methods are a more reliable method for the analysis of multi−
component samples. For these methods (cf. e.g. [95−97]), the familiar Lambert−Beer law is
written in matrix form, i.e. A = KC, where A is the matrix of sample absorbances, C the
matrix of sample concentrations, and K the matrix of proportionality constants k = εb. The
matrix equation is solved for K in the calibration step, and later for C in the analysis step. The
least squares solutions of the equation are K = ACT(CCT)−1 and C = (KTK)−1KTA, respectively.
For CCT and KTK to be invertible, the columns of C and K, respectively, have to be linearly
independent [98].
Sternberg et al. [95] demonstrated in 1960 that, in their specific application, the best results
were achieved when the analytical wavelengths were evenly spaced. Since then, many
strategies have been studied for the selection of the optimal set of analytical wavelengths in
spectroscopy. The approaches can be grouped broadly into two classes. In one class, the
analytical results between several wavelength sets are compared with the aid of standard
statistical parameters, while the wavelength sets are formed e.g. by even spacing or by
choosing the maxima, minima and crossover points in the analyte spectra [95,96,99]. In the
other class, the wavelength candidates are chosen from a large number of (evenly spaced)
19
wavelengths by awarding a figure of merit to each, hence ordering the wavelengths from
"best" to "worst". Starting with a minimum number of (best) wavelengths, the search for the
optimal wavelength combination then continues by adding the wavelength next in order to the
previous set [100−103]; finally, each combination has to be evaluated in some way. However,
the need for wavelength ranking arises from a time when computational efforts, especially
inverting a larger matrix, were non−trivial.
2.4. Mathematical treatment of kinetic data
van der Houwen et al. [50] demonstrated in 1997 that the interpretation of pH degradation
profiles is, in many cases, flawed in the scientific literature. Making some assumptions that
are not too limiting [104], the observed reaction rate constant kobs of a substance can be
expressed as a function of its n acidity constants K, the hydrogen ion concentration, and the
"macro reaction constants" M (combining kinetically indistinguishable reactions):
k
obs
=
∑
i=1
nA3 M
i
H + iB2
∑
i=0
n ∏
j=0
i
K
j
H + i
(2.1)
For a substance with one ionizable group, such as tinidazole, the above equation reduces to
[104]
k
obs
=
M
1
× H + 2AM
2
× H + AM
3
AM
4
× H + B1
H + AK
a
(2.2)
with
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M1 = k0,H (2.3)
M2 = k1,H×Ka + k’0,S×[H2O] = k1,H×Ka + k0,S (2.4)
M3 = k’1,S×Ka×[H2O] + k0,OH×Kw = k1,S×Ka + k0,OH×Kw (2.5)
M4 = k1,OH×Ka×Kw (2.6)
(The individual reaction rate constants take the form kn,N, where n = 0,1 states the number of
dissociated protons in the acid, whose Ka appears in the equations, and N = H,S,OH denotes
the other reacting species, H+, H2O (or solvent), and OH−, respectively.) A similar approach
has been adopted in the presence of ligands [105] and buffer catalysis [106]. A statistically
robust method for handling replicate cases in determining the pH degradation profile has been
described recently [107−109].
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3. Aims of the study
The primary aim of the study was to investigate the hydrolysis kinetics of tinidazole using
different analytical techniques.
The specific aims of the research were
1. to develop HPTLC and UV spectrophotometric methods for the analysis of hydrolyzed
tinidazole (II, IV)
2. to conduct a preliminary study on the alkaline hydrolysis of tinidazole by HPLC (I), and to
elucidate the hydrolysis kinetics of tinidazole over a wide pH range (III, V)
3. to study the hydrolysis mechanism(s) of tinidazole in relation to its kinetic behavior (V)
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4. Materials and methods
Only the major experimental features are described in this section. More detailed descriptions
can be found in the original publications I−V.
4.1. Materials
Tinidazole was kindly supplied by Orion Pharmaceutica (Espoo, Finland). The commercially
available 2−methyl−4(5)−nitroimidazole was from Aldrich−Chemie (Steinheim, Germany).
The 4−nitro isomer of tinidazole was prepared as described in the literature [55]. The identity
and purity of these compounds had been verified by TLC, UV, IR, as well as by 1H and
13C NMR spectrometry. For studies IV and V, another batch of the 4−nitro isomer was
prepared [55], and its identity and purity were verified by HPTLC, as well as with UV and IR
spectrometry by comparing it with the previous batch. Metronidazole, the internal standard for
HPLC (I), was obtained from the Farmos Group (Oulu, Finland). The methanol used in study I
was of HPLC grade; all other chemicals and reagents were of analytical grade. In study V,
sodium salts were used for the phosphate buffers; the ionic strengths were adjusted with
sodium chloride.
4.2. High−performance liquid chromatography (I)
The HPLC system consisted of an LKB 2150 pump, LKB 2151 variable−wavelength monitor
(LKB, Bromma, Sweden), D−2000 chromato−integrator (Merck−Hitachi, Tokyo, Japan), and
a 20 µl loop injector. The compounds were separated on a HP 79915MO−174 RP−8 column
(200 mm × 4.6 mm i.d., 10 µm particle size). The mobile phase was an isocratic mixture of
acetonitrilephosphate buffer (50 mM, pH 3) 18:82 (V/V), and the flow rate was 1.0 ml/min.
The analytical wavelength was 318 nm.
Samples from the 5 mM tinidazole solutions were prepared by mixing 1.0 ml of the
hydrolyzed solution with a sufficient volume of a neutralizing solution (0.1 M HCl) and then
diluting to 25.0 ml with water; metronidazole was added as internal standard (final
concentration 16 µg/ml). Peak area ratios (analyte to internal standard) were used for the
quantitations.
23
4.3. High−performance thin layer chromatography (II, III)
Samples were sprayed with a Linomat IV (Camag, Muttenz, Switzerland) at a speed of 15 s/µl
as 5 mm bands on silica gel HPTLC plates (Merck, Darmstadt, Germany). Methanoldiethyl
etherchloroform 1:9:3 (V/V) was used as the final mobile phase; the plates were developed
at room temperature in an unsaturated horizontal chamber (Camag). The plates were scanned
at 314 nm (D2 lamp) with a Camag TLC Scanner II controlled by the Cats 3.14 program. The
scanning speed was 4.0 mm/s, and the monochromator bandwidth was set at 10 nm. The slit
width and length were 0.2 mm and 2 mm, respectively. Each track was scanned once, and
baseline correction was used (II).
Samples from the 5 mM tinidazole solutions were prepared by mixing 1.0 ml of the
hydrolyzed solution with a sufficient volume of a neutralizing solution (0.1 M HCl or water)
and then diluting to 10.0 ml with water. Samples were applied on the HPTLC plate in
duplicate (III). Quantitations were based on peak areas and the Michaelis−Menten 1 equation
(II).
4.4. UV spectrophotometry
The UV spectrophotometric determinations (IV, V) were carried out using a Unicam UV2-300
spectrophotometer (Unicam Ltd., Cambridge, UK). The reliability of the quantitative methods
was confirmed based on the ICH guideline [25], and the specific methodology is described in
detail in paper IV.
4.4.1. Single−wavelength method (IV)
The absorbances of the solutions (pH 6.0±0.7) were measured at 318 nm against a reagent
blank using a spectral bandwidth of 1.5 nm and an integration time of 1 s. Samples from the
0.6 mM tinidazole solutions were prepared by mixing 5.0 ml of the hydrolyzed solution with
10 ml of a 0.1 M phosphate buffer and diluting to 25.0 ml with the same buffer. A second−
order polynomial was used for the calibration.
Table 4.1: Design matrix for the validation samples S1−S24 (1 = tinidazole, 2 = the 4-nitro isomer of tinidazole, 3 = 2-methyl−
4(5)-nitroimidazole).
Concentration (mM)
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24
1 0.003 0.007 0.012 0.017 0.021 0.025 0.030 0.045 0.060 0.075 0.091 0.097 0.113 0.165 0.225 0.254 0.272 0.290 0.300 0.000 0.000 0.330 0.000 0.000
2 0.007 0.290 0.017 0.272 0.025 0.254 0.045 0.226 0.075 0.165 0.113 0.091 0.097 0.060 0.030 0.021 0.012 0.003 0.000 0.300 0.000 0.000 0.330 0.000
3 0.290 0.003 0.272 0.012 0.254 0.021 0.224 0.030 0.164 0.060 0.098 0.112 0.090 0.075 0.045 0.026 0.016 0.007 0.000 0.000 0.300 0.000 0.000 0.330
sum 0.301 0.300 0.301 0.300 0.300 0.300 0.299 0.301 0.299 0.300 0.301 0.299 0.299 0.300 0.300 0.300 0.300 0.300 0.300 0.300 0.300 0.330 0.330 0.330
24
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4.4.2. Selection of analytical wavelengths for the multi−wavelength method
A set of 24 validation samples was designed (Table 4.1). The samples were prepared in a
0.1 M phosphate buffer (pH 6). The spectra of the samples were recorded at 240−290 nm at
2.0 nm intervals, i.e. at 26 wavelengths, against a reagent blank using a spectral bandwidth of
1.5 nm and a scan speed of 30 nm/min. Each sample was analyzed 7 times by changing the
solution in the cuvette between measurements (repeatability of measurement). Analyzed on
separate days, two sets of samples S1−S18 were prepared; one set of samples (S19−S24) was
analyzed on a third day. All calculations were performed within the Dataplot [110] program
suite.
Preselection of wavelengths was performed by analyzing all combinations of 4−6 wavelengths
(310,960 wavelength sets). With the nominal tinidazole concentration in unhydrolyzed
samples being 0.3 mM, wavelength combinations with all mean accuracies (n = 7) 100±10 %
and all repeatabilities ≤ 4 %, for analyte concentrations [Im] ≥ 0.03 mM (≥ 10 % of the
original amount of tinidazole in real samples), were considered acceptable.
Taking into account the results of the preselection step, a systematic search of selected
combinations of 4−20 wavelengths was conducted in the final step (786,069 wavelength sets).
Combinations with all mean accuracies 100±4 %, when [Im] ≥ 0.075 mM, and all
repeatabilities ≤ 4 %, when [Im] ≥ 0.03 mM, were selected for visual inspection, and the
combination providing the (visually) best accuracies and repeatabilities was chosen for
quantitative work.
4.4.3. Multi−wavelength method (IV)
The spectra of the solutions (pH 6.0±0.7) were recorded at 240−290 nm at 2.0 nm intervals
against a reagent blank using a spectral bandwidth of 1.5 nm and a scan speed of 30 nm/min.
For the quantitations, the absorbances at 6 wavelengths (240, 242, 246, 248, 254 and 270 nm)
were used. The results were calculated using matrix algebra.
Samples from the 0.6 mM tinidazole solutions were prepared by mixing 10.0 ml of the
hydrolyzed solution with 5 ml of a 0.1 M phosphate buffer and then diluting to 20.0 ml with
the same buffer. Samples from the 5 mM tinidazole solutions (pH 10.0) were prepared by
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mixing 3.0 ml of the hydrolyzed solution with 25 ml of 0.1 M phosphate buffer (pH 5.8) and
then diluting to 50.0 ml with the same buffer.
4.5. Preliminary degradation studies (I, III)
In order to obtain the pH degradation profile, the hydrolysis of 5 mM tinidazole solutions,
prepared in citrate−phosphate−borate/HCl buffers [111] (pH 1−12), was carried out in a
thermostated water bath at 80±0.5 °C.
The activation energy for the basic hydrolysis was calculated using the Arrhenius equation.
Hydrolysis of 5 mM tinidazole solutions, prepared in the citrate−phosphate−borate/HCl buffer
at pH 10.0 [111], was carried out in a thermostated water bath in the temperature range
60-80 °C.
4.6. Kinetic salt effect (V)
Within the pH range of 1.00−4.70, the ionic strengths varied from approximately 0.1 to 1.
Solutions of tinidazole (0.6 mM) were prepared in 0.1 M phosphate buffer by dissolving the
solid in the buffer solution at room temperature. The solutions were placed in an oven kept at
80±0.5 °C, and the samples were analyzed using the single−wavelength method.
At pH values of 7.00−8.45, the ionic strengths varied from approximately 0.2 to 1. Solutions
of tinidazole (0.6 mM) were prepared in 0.1 M phosphate buffer of appropriate pH (7.50-8.45)
by dissolving the solid in the buffer solution at 80±0.5 °C, and the containers were submerged
in a water bath kept at the same temperature. Tinidazole solutions (0.6 mM) at pH 7.00 were
also prepared in 0.1 M phosphate buffer by dissolving the solid in the buffer solution at room
temperature, and the solutions were placed in an oven kept at 80±0.5 °C. The samples were
analyzed using the multi−wavelength method.
4.7. Molecular modeling (V)
The alkaline hydrolysis mechanism of tinidazole was studied using molecular modeling. The
calculations were performed with Spartan 5.0.3 (Wavefunction Inc., Irvine, CA, USA) at the
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pBP/DN**//HF/3−21G(*) level of calculation, run on an SGI R5000 processor (SGI, Mountain
View, CA, USA).
Table 5.1: Reliability test results of the quantitative methods developed (1 = tinidazole, 2 = the 4-nitro isomer of tinidazole, 3 =
2-methyl−4(5)-nitroimidazole).
HPLC (I) HPTLC (II)
UV (IV)
Single−wavelength Multi−wavelength
1 2 3 1 2 3 1 1 2 3
Specificity Apparently stability−indicating Stability−indicating Stability−indicating Stability−indicating
Linearity Straight line Michaelis−Menten 1 calibration 2nd order polynomial Established
slopea 8651±24.71 6760±7.362 6180±6.347
y−intercept (× 10−3)a −49.93±6.023 −20.27±1.871 2.897±1.683
ra 0.9999 1.000 1.000
SSRESa 0.4928 0.1531 0.1377
Rangea
µg/ml ng on plate
10.6−106 11.0−110 5.90−59.0 21.7−174 22.1−177 21.0−168
49−120 µM (calibration)
41−150 µM (measurement) 30−330 µM
Accuracyb 105.2 % 104.6 % 103.6 % 100±2 % 100±8 %
Precisionc
Repeatabilitya < 3 % < 3 % < 1 %
Measurement of peak area 0.60 % 0.40 % 0.60 %
Measurement ≤ 0.20 % < 4 %
Positioning 0.70 % 0.60 % 1.1 %
Sample application 1.8 % 1.4 % 1.0 %
Method 5.3 % ≤ 0.25 % 1.1 % 2.5 % 1.5 %
Intermediate precision 2.4 % 2.5 % 1.5 % ≤ 1.7 % 1.3 % 1.6 % 1.0 %
Detection limit 3 ng on plate 0.247 µM 3 µM 7 µM 12 µM
Quantitation limit 20 ng on plate 0.750 µM 27.4 µM
Robustness Mobile phase compositionLaboratory temperature
pH of reaction mixture
pH of sample/standard solutions
Ionic strength of samples
Wavelength precisionc 1.0 % 0.93 % 0.89 %
a
 The data for the HPLC method were not reported in paper I, but were later calculated from the original data.
b
 mean recovery
c
 RSD
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5. Results and discussion
The main results obtained in this work are briefly described in this section. More details can
be found in the original publications I−V.
5.1. High−performance liquid chromatography (I)
The hydrolysis products were easily separated from each other, as well as from tinidazole and
the internal standard metronidazole; the total analysis time was 11 minutes (Figure 1 in paper
I). Calibration graphs for tinidazole, its 4−nitro isomer, and 2−methyl−4(5)−nitroimidazole,
had correlation coefficients better than 0.9999. This method was originally developed for the
preliminary degradation studies, and some relevant data have been collected in Table 5.1. It is
apparently stability−indicating since the reasoning given in paper II obviously applies to this
method, too: any putative degradation product involving ring−opening of the imidazole
moiety would not be expected to absorb at the detection wavelength and it would probably
have a different polarity and, hence, a different retention time from the three
5-nitroimidazoles. It also follows that this method may be used for solutions hydrolyzed at pH
1−12.
5.2. High−performance thin layer chromatography (II)
This method was developed because the earlier (HP)TLC methods [81,82,84] could not fully
resolve tinidazole and its degradation products. The chosen eluent, methanoldiethyl
etherchloroform 1:9:3 (V/V), provided baseline resolution that eliminated higher RF values
(Fig. 3 in paper II) where a rise in the baseline occurred as described in the literature [27]; the
system suitability data were acceptable (Table 1 in paper II). Methanol affected the RF values
very strongly (Fig. 4a in paper II), and more detailed studies revealed that diethyl ether was
the major factor in creating the separation enhanced by the addition of chloroform, which also
inhibited peak broadening. The method was deemed stability−indicating, and it could be used
for solutions hydrolyzed at pH 1−12.
The stability of the compounds during plate development was verified by two−dimensional
chromatography using the same mobile phase in both directions; no decomposition was
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detected at this stage. Authentic hydrolyzed samples were stable for at least 7 hours at room
temperature when kept in the dark or when applied on the plate. The compounds could be
reliably measured even 29 hours after the development of the plate, provided it was kept in the
dark (Fig. 5 in paper II).
The reliability data for the HPTLC method are presented in Table 5.1. The calculated
quantitation limit would have been less than 10 ng for each compound, but it was shown that
only at 20 ng was the repeatability of sample application less than 3 % (Table 2 in paper II),
which is the acceptance criterion [112]. The precision tests confirmed that the method,
including the analytical equipment, is free of any large random errors. On the other hand,
although the method passed the accuracy test, it had a slight positive bias, which was
especially pronounced at the lower end of the range. Taking into account the intended use of
the method, this could be overlooked because of the possible experimental errors in kinetic
studies.
5.3. UV spectrophotometry
The UV spectra of tinidazole and its hydrolysis products are depicted in Figure 2 in paper IV.
Tinidazole imposes the strictest demands on the pH of any hydrolyzed solution whose
constitution should be analyzed by UV spectrophotometry. Spectral and stability
considerations lead to the demand that the pH of such solutions be 5.00−7.00. The reliability
data (IV) for both methods are presented in Table 5.1.
5.3.1. Single−wavelength method (IV)
This method should only be used for analyzing reactions taking place within the pH range of
1.00−5.00, where the product profile is known to lack any strong interferants at 318 nm. The
pH of the samples and standard solutions should be adjusted to 6.00±0.70 with a 0.1 M
phosphate buffer of appropriate pH. The HPTLC sample stability data (II) apply to this
method, too. Sample ionic strengths of 0.1−0.5 were well tolerated without any spectral
changes for tinidazole at 318 nm. It was shown that quadratic fitting, i.e. a second−order
polynomial, is better than a straight line for calibration.
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5.3.2. Selection of analytical wavelengths for the multi−wavelength method
The preselection step revealed the following: there were about 1000 acceptable 4−6
wavelength combinations, one of the wavelengths was always 240 nm or 242 nm, and
wavelengths between 258−268 nm (limits included) never occurred. The large number of
acceptable combinations would have led to an overwhelming amount of results requiring some
form of screening, e.g. visual inspection. On the other hand, the total run time would have
grown prohibitively long since the analysis of all 4−26 wavelength combinations
(approximately 67.1 million) would have taken almost 9 years! It was also noticed that the
accuracy for some compounds in some of the samples was very sensitive to the choice of
wavelengths (Figure 5.1). Since the applied accuracy criteria were rather loose, it was decided
to choose a tighter accuracy range for the final selection step that would bring these values as
near 100 % as possible. To shorten the analysis time in the final step, the wavelengths of
258-268 nm (limits included) were omitted and at least one of 240 nm and 242 nm had to be
included in acceptable combinations.
In the final step, only 13 wavelength combinations had to be evaluated visually. All
acceptable combinations had 4−7 wavelengths; no 8−wavelength or higher combinations
passed the criteria. All the acceptable wavelength combinations apart from the best one
yielded rather similar results, especially in respect of the sensitive points, i.e. the ones
showing potential outlier behavior. The best combination was formed by 6 wavelengths: 240,
242, 246, 248, 254, and 270 nm (Figure 5.1). This wavelength combination was used in all the
multi−wavelength analyses.
5.3.3. Multi−wavelength method (IV)
This method should only be used for analyzing reactions taking place within the pH range
6.00−12.00. The requirements for sample and standard pH, as well as for the storage of
samples, are identical to the single−wavelength method.
This method showed an accuracy comparable to the accuracy at low−range of the HPTLC
method (II). All the calculated individual accuracies fell between 100±10 % for [Im] ≥
0.03 mM. These values are very adequate for kinetic purposes, and they totally lacked
deviations > 10 % seen with the HPTLC method (II). This method seemed to lack the positive
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bias seen with the HPTLC method (II), as well (Figure 5.1, Table 4 in paper IV). The
repeatability of measurement was better than 3 % for [Im] ≥ 0.03 mM apart from one value
which lied below the 4 % limit (Figure 5.1). Comparable repeatabilities for the HPTLC
method (II) were calculated at approximately mid−range. In this respect, these two methods
are similar. The intermediate precision was clearly better than within−laboratory
reproducibility for the HPTLC method (II). Due to methodological differences, the
repeatabilities of the method cannot be compared.
Figure 5.1: Accuracies and repeatabilities of measurement for a typical 4−7 wavelength
combination in the final step (a) and the best 6−wavelength combination (b): tinidazole (Z),
its 4−nitro isomer (6) and 2−methyl−4(5)−nitroimidazole (%). Some sensitive points have
been marked with an arrow.
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5.3.4. Cross−validation (IV)
The single−wavelength and multi−wavelength UV spectrophotometric methods were cross−
validated. Analysis of variance identified the analytical method (confidence level: 99.61 %)
and the ionic strength of the tinidazole solution (96.99 %) as significant factors, whereas the
analysis date was statistically non−significant (44.53 %). It was therefore concluded that these
UV spectrophotometric methods are not equal; the multi−wavelength method always gave
higher concentrations of tinidazole (typically by 2−3 %).
Figure 5.2: The pH degradation profiles of tinidazole ($; −−− paper I,  paper III, ··· paper
V) and metronidazole (♦) [47].
5.4. pH degradation profile (I, III, V)
The hydrolysis of tinidazole followed apparent first−order kinetics in almost all of the studied
cases (I, III−V); for exceptions, cf. Table 1 in paper III. It can be clearly seen that, at 80 °C,
tinidazole is hydrolytically most stable at pH 4.0−5.0 (Figure 5.2). However, tinidazole has
been reported to exhibit constant hydrolytic stability at 70 °C over the pH range 3.00−6.50
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[61]. For comparison, metronidazole has maximum stability around pH 5.0 [34,47]. Despite
slightly different reaction conditions [47], metronidazole clearly seems to be more stable in
alkaline solutions than tinidazole. One possible reason for the difference was proposed (III) to
be the intrinsic stability of metronidazole. It was considered (III) plausible that tinidazole
would decompose by a different mechanism in basic and acidic conditions, while
metronidazole would be degraded by a single mechanism, which could be identical to that of
tinidazole in acidic conditions. This postulation was considered to be substantiated by the
different product profiles of acid− and base−catalyzed hydrolysis of tinidazole. However, it
was found (III) that the determined pH profiles (I, III) suffered from a lack of constant ionic
strength, thereby warranting a study of the kinetic salt effect in order to gain an insight into
the reaction mechanisms in question.
5.5. Activation energy (I, III)
The activation energy for the basic hydrolysis of tinidazole at pH 10.0 was calculated to be
130.9 kJ/mol (I) and 122 kJ/mol (III) (31.3 kcal/mol and 29.2 kcal/mol, respectively). These
values are in good agreement with each other, as well as with a recent study [61] that reported
a value of 133 kJ/mol at pH 5.25. For the hydrolysis of metronidazole, the activation energy at
pH 8.0 is 26.6 kcal/mol [47].
5.6. Reaction mechanisms (V)
It was shown that, in all the studied cases, within the pH range of 1.00−8.45 at least one of the
reacting partners contributing to the transition state in the hydrolysis of tinidazole had a
charge of 0 in the major degradation pathway. In alkaline conditions (pH ≥ 7) tinidazole is
mainly decomposed through reaction between the uncharged tinidazole and the hydroxide ion.
In mildly acidic conditions (around pH 4.5), the course of the reaction is governed by solvent−
assisted degradation of the nitroimidazole moiety in the uncharged tinidazole. In more acidic
conditions, the nitroimidazole structure is also decomposed, but it was not possible to
elucidate whether it is tinidazole in the charged or uncharged form that reacts, or both.
The mechanism in Scheme 1 in paper V was proposed for the alkaline hydrolysis of tinidazole
(Table 3 in paper V). A stable encounter pair between the hydrated hydroxide ion (4 H2O)
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[113] and tinidazole was present in the gas phase in a micro−hydrated environment. The
transition state described a proton transfer to the hydroxide ion. The deprotonated tinidazole
was then able to decompose to ethyl vinyl sulfone and the deprotonated 2-methyl−
4(5)-nitroimidazole through another transition state. The activation energy of the hydrolysis
reaction could not be reproduced at the calculation level used. Although the scheme involves a
cascade of reactions, it cannot be excluded that the proton transfer and formation of ethyl
vinyl sulfone may take place simultaneously.
5.7. Hydrolysis products (I−V)
The formation of 2−methyl−4(5)−nitroimidazole was not of the first−order, apparently
because of the small amounts of the 4−nitro isomer formed at the same time (I, IV, V); this
was corroborated by the HPTLC study (III). Quantitation of the 4−nitro isomer in hydrolysis
solutions was usually not possible because of the very small amounts formed (I, IV, V). These
results were characteristic of the pH range 6.0−12.0 (I, III−V). Addition of the hydrolysis
products did not significantly affect the hydrolysis rate of tinidazole (IV). At pH ≤ 5, the
4-nitro isomer and 2−methyl−4(5)−nitroimidazole were absent in hydrolyzed tinidazole
solutions (III, IV). It should be further noted that, apart from tinidazole and the two hydrolysis
products, no other 5−nitroimidazole species have been detected in hydrolyzed tinidazole
solutions within the pH range of 1−13 [36 and present studies I−III].
The hydrolysis of the 4−nitro isomer and 2−methyl−4(5)−nitroimidazole were studied (IV) at
pH 10.0 and 80 °C. The decomposition rate of the 4−nitro isomer was approximately 30 times
slower than that of tinidazole; the reaction yielded an almost quantitative amount of
2-methyl−4(5)-nitroimidazole and only a very small amount of tinidazole. 2-methyl−
4(5)-nitroimidazole did not decompose at all under the test conditions.
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6. Conclusions
An HPTLC method and two UV spectrophotometric methods were developed for the analysis
of hydrolyzed tinidazole. The HPTLC method was shown to be stability indicating and robust.
Tinidazole and its two hydrolysis products were stable enough before, during, and after
chromatography to enable analyses to be carried out easily. The method was found to be free
of any large random errors. It had a slight positive bias, which could be overlooked because of
the possible experimental errors in the kinetic studies. Thus, the HPTLC method could be used
reliably for monitoring the hydrolysis kinetics of tinidazole.
The UV spectrophotometric methods were stability−indicating and robust. The single−
wavelength method is suited for analyzing reactions taking place within the pH range of 1−5,
whereas the multi−wavelength method can be used for tinidazole solutions hydrolyzed at pH
6−12. The multi−wavelength method gave validation parameters comparable to the HPTLC
method, but it lacked the positive bias. Both methods could be reliably used for kinetic
purposes, although cross−validation indicated that they produce statistically different results.
The feasibility of systematic wavelength searching in developing multi−wavelength
spectrophotometric methods was demonstrated using the precision and accuracy of validation
samples as selection criteria.
The hydrolysis of tinidazole followed apparent first−order kinetics in most of the conditions
studied. At 80 °C, tinidazole was hydrolytically most stable between pH 4.0−5.0, and it was
clearly more labile in alkaline conditions than metronidazole, which is the most frequently
used 5−nitroimidazole. Over the pH range 1.00−8.45, at least one of the reacting partners
contributing to the transition state had a charge of 0 in the major degradation pathway. The
dominant reactions were tinidazole + OH− at pH ≥ 7 and tinidazole + H2O around pH 4.5. In
more acidic conditions, the reaction tinidazole + H+ and/or [tinidazole+H]+ + H2O took place;
the existence of [tinidazole+H]+ + H+ could be neither excluded nor corroborated. The
suggested alkaline hydrolysis mechanism involved a proton transfer from tinidazole to the
hydroxide ion and the formation of ethyl vinyl sulfone. The reactions may occur either in a
step−wise manner or simultaneously. The reaction was qualitatively verified by computational
methods. The activation energy of the hydrolysis reaction, which was determined to be ca.
120−130 kJ/mol, could not be reproduced.
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The formation of 2−methyl−4(5)−nitroimidazole over the pH range 6−12 was not of first−
order, apparently because of the small amounts of the 4−nitro isomer of tinidazole formed at
the same time. At pH ≤ 5, these products could not be detected. Apart from tinidazole and the
two hydrolysis products, no other 5−nitroimidazole species were detected in hydrolyzed
tinidazole solutions over the pH range 1−12.
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